The original rise of Viagra presented a massive opportunity for investors , but its exclusivity has ended, creating a complex landscape. Generic versions have entered the space , cutting into revenues and putting a strain on profit percentages . While established healthcare companies continue a presence in this field , the outlook looks unclear by